Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02489773 · ClinicalTrials.gov registry record
Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study
A clinical trial of Diabetes, sponsored by Asahi Kasei Pharma Corporation.
- Completed
- Registry status
- 150
- Enrollment target
- 8
- Study locations
NCT02489773: Completed study of Diabetes, sponsored by Asahi Kasei Pharma Corporation.
NCT02489773 is a study of Diabetes that has completed, run by Asahi Kasei Pharma Corporation. The registered enrollment target is 150 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (95% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02489773, a study of Diabetes, has completed, sponsored by Asahi Kasei Pharma Corporation.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
- 8
- Study locations
Study Summary
To confirm that Lucica ® Glycated Albumin-L is useful for the intermediate term (preceding 2-3 weeks) monitoring of glycemic control in patients with diabetes.
Conditions Studied
Study Locations (8)
California
- National Research Institute - Huntington Park - Los Angeles
- National Research Institute-Westlake - Los Angeles
Texas
- Texas Diabetes & Endocrinology, P.A. -Austin - Austin
- Dallas Diabetes and Endocrine Center - Dallas
Kentucky
- Kentucky Diabetes Endocrinology Center - Lexington
Louisiana
- Tulane University - New Orleans
Nebraska
- University of Nebraska Medical Center - Omaha
Washington
- Capital Clinical Research Center - Olympia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-07 |
What the finished NCT02489773 record still lists
NCT02489773 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 0 interventions.
NCT02489773 lists 8 locations in 6 states (California, Texas, Kentucky).
Frequently Asked Questions
What is clinical trial NCT02489773 about?
NCT02489773 is a clinical study titled "Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study". To confirm that Lucica ® Glycated Albumin-L is useful for the intermediate term (preceding 2-3 weeks) monitoring of glycemic control in patients with diabetes.
What is the current status of trial NCT02489773?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2015-06. Estimated completion is 2016-07.
What conditions does trial NCT02489773 study?
This clinical trial studies the following conditions: Diabetes.
Who is sponsoring clinical trial NCT02489773?
This trial is sponsored by Asahi Kasei Pharma Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02489773 being conducted?
This trial has 8 study locations across California, Kentucky, Louisiana, Nebraska, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02489773's enrollment target sits among peer trials
150 165th of 338 higher than 168 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DFC 004 Biomarkers for Active Diabetic Foot Ulcers
RECRUITING
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Taste Bud-Derived Stem Cells in Humans
RECRUITING
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia